Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting

Phase 1

Intranasal VaccineSafety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Sponsor:

Meissa Vaccines, Inc.

Code:

NCT04909021

Conditions

Respiratory Syncytial Virus (RSV)

Eligibility Criteria

Sex: All

Age: 6 - 36

Healthy Volunteers: Accepted

Interventions

Investigational RSV vaccine MV-012-968 (Dosage 1)

Investigational RSV vaccine MV-012-968 (Dosage 2)

Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)

Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)

Placebo (single-dose)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Meissa Vaccines, Inc. on 2022-08-02.